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Abstract
Background: Extensive uterine adaptations, including angiogenesis, occur prior to implantation in early pregnancy
and are potentially regulated by the peptide hormone relaxin. This was investigated in two studies. First, we took a
microarray approach using human endometrial stromal (HES) cells treated with relaxin in vitro to screen for target
genes. Then we aimed to investigate whether or not relaxin deficiency in mice affected uterine expression of
representative genes associated with angiogenesis and uterine remodeling, and also blood vessel proliferation in
the pre-implantation mouse endometrium.
Methods: Normal HES cells were isolated and treated with recombinant human relaxin (10 ng/ml) for 24 h before
microarray analysis. Reverse transcriptase PCR was used to analyze gene expression of relaxin and its receptor
(Rxfp1) in ovaries and uteri; quantitative PCR was used to analyze steroid receptor, angiogenesis and extracellular
matrix remodeling genes in the uteri of wild type (Rln+/+) and Rln-/- mice on days 1-4 of pregnancy.
Immunohistochemistry localized endometrial endothelial cell proliferation and mass spectrometry measured steroid
hormones in the plasma.
Results: Microarray analysis identified 63 well-characterized genes that were differentially regulated in HES cells
after relaxin treatment. Expression of some of these genes was increased in the uterus of Rln+/+ mice by day 4 of
pregnancy. There was significantly higher vascular endothelial growth factor A (VegfA), estrogen receptor 1 (Esr1),
progesterone receptor (Pgr), Rxfp1, egl-9 family hypoxia-inducible factor 1 (Egln1), hypoxia inducible factor 1 alpha
(Hif1α), matrix metalloproteinase 14 (Mmp14) and ankryn repeat domain 37 (Ankrd37) in Rln-/- compared to Rln+/+
mice on day 1. Progesterone receptor expression and plasma progesterone levels were higher in Rln-/- mice
compared to Rln+/+ mice. However, endometrial angiogenesis was not advanced as pre-implantation endothelial
cell proliferation did not differ between genotypes.
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Conclusions: Relaxin treatment modulates expression of a variety of angiogenesis-related genes in HES cells.
However, despite accelerated uterine gene expression of steroid receptor, progesterone and angiogenesis and
extracellular matrix remodeling genes in Rln-/- mice, there was no impact on angiogenesis. We conclude that
although relaxin deficiency results in phenotypic changes in the pre-implantation uterus, endogenous relaxin does
not play a major role in pre-implantation angiogenesis in the mouse uterus.
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Background
To start a pregnancy, the endometrium must be in a re-
ceptive state for embryo implantation. In women, the
endometrium undergoes extensive vascular growth, re-
modeling, and regression on an approximately monthly
basis [1]. During the proliferative phase of the cycle, the
endometrium and its associated vasculature undergo a
period of rapid growth, with subsequent maturation oc-
curring in the secretory phase [2]. Failure of the endo-
metrium to appropriately remodel and vascularize can
result in miscarriage and other pregnancy complications
such as fetal growth restriction [3, 4].
Growth, maturation and remodeling of the endometrium
and its blood vessels are primarily regulated by the ovarian
steroid hormones estrogen and progesterone [5, 6]. In
mice, endometrial endothelial cell proliferation increases
prior to embryo implantation in response to increasing
plasma progesterone concentrations. Progesterone treat-
ment in ovariectomized mice stimulates angiogenesis; es-
trogen priming moderates this progesterone-induced
endothelial cell proliferation [6]. The peptide hormone re-
laxin also contributes to remodeling in early pregnancy in
primates [7]. Although primarily ovarian in origin, relaxin
is also produced by other tissues during pregnancy, includ-
ing the endometrium, where it is hypothesized to exert
paracrine and autocrine uterotrophic effects [8, 9]. Relaxin
treatment of ovariectomized rats and rhesus monkeys
primed with estrogen increases uterine weight relative to
controls, and also causes increased arteriole number per
unit area, dilated blood vessels on the endometrial luminal
surface and pronounced endothelial cell proliferation in ar-
terioles and capillaries of the endometrium [9–12]. Im-
plantation bleeding and increased endometrial thickness
are observed in relaxin-treated macaque and marmoset
monkeys [13, 14], with slightly higher implantation rates
following in vitro fertilization and embryo transfer in the
macaques [14]. In the context of human physiology,
women in a clinical trial for the treatment of scleroderma
reported heavier or irregular menstrual bleeding if they
were treated with relaxin, possibly due to increased endo-
metrial vascularization [15, 16].
Few studies have investigated the direct effects of re-
laxin on endometrial remodeling and angiogenesis, al-
though relaxin receptors are expressed in the human
endometrium and relaxin is known to modify the ex-
pression of numerous key regulatory factors [17–20].
For instance, in rhesus macaques relaxin treatment in-
hibits endometrial estrogen receptor α (ERα), progester-
one receptor A (PRA) and progesterone receptor B
(PRB) protein levels [9]. Relaxin also stimulates expres-
sion and secretion of the pro-angiogenic factor vascular
endothelial growth factor (VEGF) in normal human
endometrial stromal and glandular epithelial cells in a
dose-dependent manner in vitro [15, 21]. This activation
occurs through ERα [22]. Relaxin treatment in macaques
has negative impacts on matrix metalloproteinase
(MMP) expression causing decreased pro-MMP and an
increase in the MMP inhibitor tissue inhibitor of metal-
loproteinase 1 (TIMP1) [9]. Although these studies pro-
vide evidence to support a role for relaxin in uterine
vascularization and remodeling in the pre-implantation
period, they are limited in their analysis of angiogenesis-
related genes. Therefore, the first aim was to undertake
a more comprehensive microarray approach using hu-
man endometrial stromal (HES) cells treated with re-
laxin in vitro to identify candidate angiogenesis-related
genes for further investigation.
The relaxin gene knockout (Rln-/-) mouse provides a
model to investigate endogenous relaxin physiology in
the pre-implantation period in vivo; fetal weights in late
pregnancy and pup weight at birth are both significantly
reduced, suggesting that mice born to Rln-/- mice are
growth restricted in utero [23, 24]. Based on the relaxin
treatment effects in rodents and rhesus monkeys [9–14],
we predicted that this growth restriction could be due to
reduced uterine angiogenesis and remodeling in the
uterus of Rln-/- mice. Therefore, the second aim of this
study was to investigate whether or not relaxin defi-
ciency affected uterine expression of representative
genes associated with angiogenesis and uterine remodel-
ing, and also blood vessel proliferation in the pre-
implantation endometrium (days 1–4 of pregnancy in
mice). This time frame was selected so we could focus
on the endometrial changes that occur prior to implant-
ation and independently of any influence from the
implanting embryo. As there are no data on paracrine
relaxin signaling (relaxin and relaxin receptor, Rxfp1,
expression) in the mouse uterus, a third aim was to
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demonstrate that relaxin receptors are present in the
endometrium and that there is a uterine source of re-
laxin in early pregnancy.
Methods
Animals
All animal experiments were approved by The University
of Melbourne Animal Experimental Ethics Committee
(AEEC #0911478.1) and conducted in accordance with
the Australian Code of Practice and the National Health
and Medical Research Council. This study used wild type
(Rln+/+) and Rln-/- mice. Homologous recombination in
embryonic stem cells was used to disrupt the relaxin gene
by deleting a region essential for biological activity and re-
placing it with the neomycin transferase gene [25]. Rln-/-
mice were then backcrossed to a C57/BLK6J background
and the F14 generation relocated to the School of BioSci-
ences. Genotypes were confirmed by PCR analysis of gen-
omic DNA from ear clips as previously described [25].
Mice were maintained on an automated time cycle of 12 h
light/dark at 20 °C, with laboratory chow (Barastock,
Pakenham,VIC, Australia) and water available ad libitum.
Identification of RXFP1 in the endometrium
of Rxfp1TG mice
Uterine tissues from non-pregnant transgenic mice with
a modified Rxfp1 gene (n = 3) were kindly provided by
Prof AI Agoulnik (Florida International University,
Miami, FL, USA). The modification is a 4 kb fragment
containing parts of exons 15 and 17 that was ligated into
a SalI site of the pNTR-LacZ/PGKneo/loxP vector as
described by Kamat et al [26]. During homologous inte-
gration, the targeting vector was inserted into exon 17
and created a duplication of the 4 kb genomic fragment.
Uterine tissues were dissected from Rxfp1TG mice after
anesthetic overdose and were fixed in 2 % paraformalde-
hyde in 1X phosphate buffered saline/MgCl2 for 30 mins
at RT. Tissues were then embedded in Tissue-Tek OCT
compound (Sakura Finetechnical Co. Ltd), and cryosec-
tions were cut at 10 μm and mounted on Superfrost
slides. For histological analysis of LacZ expression, tis-
sues sections were processed for X-gal staining using the
LacZ Detection Kit for Tissues (InvivoGen) according to
the manufacturer’s instructions. Nuclei were then coun-
terstained with 0.1 % nuclear fast red and mounted in
aqueous mounting medium. Control tissues were ob-
tained from wild type littermates.
Effects of relaxin treatment on human endometrial
stromal cells in vitro
HES cells were isolated from a collagenase-treated uterus
of a pre-menopausal woman who had a hysterectomy for
reasons other than uterine disease, with informed consent
and approval from the institutional review board [15, 27].
Stromal cells obtained from a normal uterus were cul-
tured in 75 mm2 flasks, and fed every two days with
DMEM:F12 medium plus 10 % newborn calf serum and
2 mM L-glutamate. These cells have previously been
shown to possess high affinity relaxin binding sites [15]
and to produce cAMP in response to relaxin [27]. Once
confluent, the cells were washed with phosphate buffered
saline (PBS) and treated in serum-free DMEM:F12
medium with either vehicle alone or with recombinant
human relaxin (rhRLX) (Connetics Corporation, Palo
Alto, CA, USA) (10 ng/ml) for 24 h. This concentration
and duration was shown to be bioactive in a previous
study [15]. Total RNA was isolated using Trizol (Invitro-
gen) according to manufacturer’s instructions. Total RNA
from 8 HES cell cultures treated with vehicle or with
rhRLX were pooled to yield 100 μg RNA each. This was
sent to Incyte Genomics (Palo Alto) for extraction of
PolyA-RNA and subsequent microarray analysis [28].
Briefly, 600 ng of polyA-RNA of each sample was used for
reverse transcription and attachment of the appropriate
cyanine (Cy) dye. The Cy3- and Cy5-labelled probes were
then mixed, and simultaneously hybridized to a single
cDNA microarray. Following incubation, the array was
washed in 3 consecutive washes of decreasing ionic
strength, and scanned in both Cy3 and Cy5 channels using
GenePix scanners (Foster City). Incyte GEMtools software
was used for image analysis. Background-subtracted elem-
ent signals are used to calculate Cy3:Cy5 ratios. Default
criteria in GEMtools analysis are that the signal-to- back-
ground ratio > 2.5 for each element, and that the area for
which pixel values are counted is at least 40 % of the elem-
ent for both signals. The ratio of fluorescent intensities
from the two dyes were used to assess relative transcript
abundance in the two RNA samples. The minimum de-
tectable fold change for differential expression, according
to evaluation of the performance of the Incyte array, is
1.4-fold [29], i.e. expression in mRNA from rhRLX-treated
cells 1.4-fold higher than in vehicle-treated cells, or vice
versa.
Effects of relaxin deficiency in early pregnancy
In Study 1, Rln+/+ mice were studied on days 1, 2, 3 and
4 of pregnancy to assess changes in gene expression in
the wild type mice (n = 8/genotype/day). Based on data
from Study 1, we then chose to examine pre-implantation
phenotypes in Rln+/+ and Rln-/- mice only on days 1 and 4
of pregnancy (Study 2, n = 8/genotype/day). In Study 3,
gene expression alone was examined in an additional
group of mice on day 6 of pregnancy (n = 7/genotype) to
examine if phenotypes persisted after implantation (Add-
itional file 1: Figure S1). Female mice aged 2–4 months
were housed with a stud male of matched genotype over-
night and then checked for mating plugs the following
morning. The presence of a mating plug was an indication
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of successful mating and was considered day 1 of preg-
nancy. Four hours prior to tissue collection, mice received
a 500 μl i.p. injection of bromodeoxyuridine (BrdU; 2 mg/
ml, Sigma-Aldrich Pty Ltd), enabling later visualization of
proliferating cells by immunohistochemistry. After iso-
fluorane anesthesia, blood was collected by cardiac
puncture and the plasma stored at -80 °C. After cervical
dislocation, the uterine tissues were removed with half
fixed in 10 % neutral buffered formalin overnight before
processing for paraffin sections, and the other half
stored at -80 °C for gene expression analysis.
Analysis of gene expression
Total RNA was isolated from whole uteri using Trizol
reagent (Invitrogen) according to the manufacturer’s in-
structions. The concentration of RNA was determined
using a NanoDrop ND100 Spectrophotometer (Nano-
Drop Technologies Inc) with A260:A280 absorbance
ratios of > 2.0 indicating sufficiently pure RNA for PCR
analysis. First strand cDNA synthesis used 1 μg total
RNA in a 20 μL reaction, using random hexamers
(50 ng/μL), 10 mM dNTP and 200 U SuperScript III
(Invitrogen). First-strand cDNA synthesis for all sam-
ples were performed simultaneously at 25 °C for
10 min, 50 °C for 50 min and 85 °C for 5 min. Quanti-
tative reverse-transcription polymerase chain reaction
(quantitative PCR) was performed to assess the relative
expression of relaxin (Rln) and its receptor Rxfp1 and
key genes chosen to represent angiogenesis (total
VEGFA (VegfA), VEGF receptor 2 (Vegfr2)), steroid re-
ceptors (estrogen receptor (ER)-α (Esr1), ER-β (Esr2),
progesterone receptor (Pgr)), tissue remodeling (matrix
metalloproteinase 14 (Mmp14), Timp3)), and other key
genes identified in our microarray analysis (ankryn repeat
domain 37 (Ankrd37), egl-9 family hypoxia-inducible
factor 1 (Egln1), hepatocyte growth factor (Hgf ), hypoxia
inducible factor 1α (Hif1α)). In addition to these genes
investigated pre-implantation, interleukin 1β (Il1β) was
also investigated post-implantation (Additional file 2:
Figure S2). Forward and reverse primers and 6-carboxy
fluorescein (FAM)-labeled TaqMan probes specific for
mouse genes were designed to span an intron/exon
junction (Biosearch Technologies, Inc). Primer se-
quences are shown in Additional file 3: Table S1. All
quantitative PCR reactions for each gene were per-
formed on one plate, in 10 μl or 20 μl 96-well reactions
containing SensiFAST Probe Lo-Rox (BioRad) and per-
formed in the ViiA™7 Real-Time PCR System (Life
Technologies). Recent data suggest that glyceraldehyde
3-phosphate dehydrogenase (Gapdh) and 18 s ribosomal
RNA (18 s) expression are upregulated in the rodent
uterus in response to progesterone and estrogen [30,
31]. The same pattern of 18 s mRNA expression was ob-
served in this study so we investigated peptidylprolyl
isomerase A (Ppia), succinate dehydrogenase complex,
subunit A (Sdha) and TATA box binding protein (Tbp)
as reference genes; however, these were also significantly
increased from days 1 to 4 of pregnancy (Additional file 2:
Figure S2). Therefore we used the mean CT value of the
Rln+/+ mice on day 1 of pregnancy as the internal calibra-
tor and subtracted this from the mean gene of interest
triplicate CT value (Ratio(test/calibrator) = 2
ΔCT, where ΔCT =
CT(calibrator) − CT(test)) as has been described previously
[30, 32]. These “normalized” data (ΔCT) were pre-
sented as fold induction relative to day 1 of pregnancy
in the Rln+/+ mice. The mean CT values and range CT
values for each gene are presented in Additional file 3:
Table S2.
The presence or absence of relaxin (Rln) and Rxfp1
gene transcripts in the uterus and ovaries were assessed
by reverse transcriptase polymerase chain reaction (RT-
PCR) in the GeneAmp PCR system 2700 (Applied Bio-
systems). Reaction mixes consisted of GoTaq Green
(Promega), mouse-specific oligonucleotide primers
(100 ng/μl) designed to span an intron/exon junction
(Additional file 3: Table S3) and 1 μl cDNA. Ovary RNA
was extracted as described above.
Immunohistochemistry
As the study focused on pre-implantation vascular re-
modeling, we used immunohistochemistry to examine
endometrial endothelial cell proliferation as a marker of
endometrial angiogenesis. We used a dual immunohisto-
chemistry protocol with antibodies against CD31 (pan-
endothelial cell marker) and BrdU (labels proliferating
cells). After dewaxing and rehydration, sections (5 μm)
were incubated with 0.1 % (1 mg/ml) pepsin in 3 %
acetic acid for 10 min at 37 °C, followed by serum free
protein block (Dako) for 15 min to prevent non-specific
binding. Sections were incubated with rat monoclonal
anti-mouse CD31 (5 mg/ml in 1 % bovine serum albu-
min in PBS (BSA/PBS) (BD PharMingen)) overnight at
4 °C. Sections were then incubated for 1 h at room
temperature in biotinylated goat anti-rat IgG (1:200 in
1 % BSA/PBS, Chemicon), followed by incubation in al-
kaline phosphatase conjugated streptavidin (Dako) for
15 min. CD31-positive immunostaining was visualized
using the vector blue alkaline phosphatase chromagen
(10 min, Vector Laboratories). Sections were then incu-
bated in 0.1 M HCl for 45 min at room temperature,
followed by a further incubation 3 % H2O2 in PBS for
10 min at room temperature to quench endogenous per-
oxidase. Serum free protein block was applied for a fur-
ther 15 min. Sections were incubated for 1 h at room
temperature in monoclonal sheep anti-BrdU (8 μg/ml in
1 % BSA/PBS, Abcam). This was followed by a further
incubation for 1 h at room temperature in donkey anti-
sheep IgG (4 μg/mL in 1 % BSA/PBS, Jackson Immuno
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Research Laboratories). Sections were then incubated
in streptavidin horseradish peroxidase (Dako) for
15 min, followed by 5 min in DAB chromagen (3,30-
diaminobenzidine, Sigma-Aldrich) to visualize BrdU
immunostaining. Each slide contained a negative iso-
tope matched control section that was prepared by re-
placing the CD31 primary antibody with rat IgG2a
(BD Biosciences) and the BrdU primary antibody with
sheep IgG (Sigma-Aldrich) at the same concentrations
as that of the primary antibodies. For the main ana-
lysis, we analyzed one section per uterus (n = 7/group)
taken from the mid-point between the cervix and
ovaries. The number of proliferative endothelial cells
and the number of blood vessel profiles present in the
endometrial tissue on each section were counted. Data
are presented as the proportion of vessel profiles
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Fig. 1 a Reverse transcriptase PCR (RT-PCR) expression of Rxfp1 in the uterus of wild type (Rln+/+) and relaxin deficient (Rln-/-) mice in early
pregnancy. The positive control for Rxfp1 was the cervix (CX). Note the two RXFP1 isoforms. The negative control was water (H2O). IV = Hyperladder
OV. b Quantitative PCR analysis of Rxfp1 mRNA in the uterus of Rln+/+ mice from days 1 to 4 of pregnancy (Study 1), and in Rln+/+ and Rln-/- mice on
days 1 and 4 (Study 2) (n = 6–8). c RT-PCR expression of relaxin (Rln) and Gapdh in the uterus and ovaries of Rln+/+ and Rln-/- mice in early pregnancy.
d Quantitative PCR analysis of Rln mRNA in the uterus of Rln+/+ mice from days 1 to 4 of pregnancy. Expression is shown as the fold change compared
with the mean gene expression in Rln+/+ mice on day 1 of pregnancy. Horizontal bars indicate mean values. Groups within each study that do not
share a letter are significantly different from one another, *denotes a significant difference between day 1 and 4 of pregnancy in study 2, significance
is p < 0.05
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containing one or more proliferating endothelial cells,
and as the number of proliferating endothelial cells
per mm2 (identified using a × 40 objective lens).
Steroid analysis
Plasma progesterone and corticosterone concentrations
were measured by triple quadrupole mass spectrometry
(Eric Thorstensen, Liggins Institute, University of Auck-
land, Auckland, New Zealand). Estrogen could not be
measured as there was insufficient plasma for accurate
detection. An internal standard solution (60 ng mL-1
corticosterone-d8 and 0.2 ng mL-1 estradiol-d3 in water)
was added to each plasma sample (100 μL standard to
200 μL plasma). Steroids were then extracted using
1 mL of ethyl acetate (Merck). After removal of the or-
ganic supernatant to a clean tube, samples were dried by
vacuum concentration (Savant SC250EXP, Thermo Sci-
entific), resuspended in 60 μL of mobile phase (45 %
methanol and 55 % water) and transferred to HPLC in-
jector vials. Samples (12 μL) were injected onto an
HPLC mass spectrometer system consisting of an Accela
MS pump and autosampler followed by an Ion Max
APCI source on a Finnigan TSQ Quantum Ultra AM
triple quadrupole mass spectrometer all controlled by
Finnigan Xcalibur software (Thermo Electron Corpor-
ation). The mobile phase was a gradient of methanol
and water, flowing at 400 μL.min-1 through a Hypersil
Gold 1.9 μm C18 50 ×2.0 mm column at 40 °C (Thermo
Fisher Scientific). Retention time was 6.2 min for proges-
terone and 2.3 min for corticosterone. Ionization was in
positive mode for progesterone, Q2 had 1.2 mTorr of
argon. The mass transitions followed were: progesterone
315.5→ 109.2 at 22 V and corticosterone 347.2→ 121.0
at 27 V.
Statistical analysis
Proliferating endothelial cell number and circulating
steroid hormone concentrations were assessed by two-way
ANOVA (genotype v day of pregnancy) and Tukey post-
hoc tests (SPSS Inc.). Changes in gene expression during
early pregnancy in the Rln+/+ mice were assessed by one-
way ANOVA (day of pregnancy) and Tukey post-hoc tests.
Two-way ANOVA with genotype and day of pregnancy as
main effects assessed any interaction between genotype
and day of pregnancy in the Rln+/+ and Rln-/- mice followed
by Tukey post-hoc tests to compare means of all groups.
T-tests were used to examine gene expression differences
between Rln+/+ and Rln-/- mice on day 6 of pregnancy. If
not normally distributed, raw data were log transformed
and non-parametric analysis was performed using Mann-
Whitney with Bonferroni correction. All figures are
graphed using the untransformed fold change data.
Results
Relaxin signaling in early pregnancy
Reverse transcriptase PCR confirmed the presence of
two gene transcripts for Rxfp1 representing both iso-
forms in the uterus of both Rln+/+ and Rln-/- mice in
early pregnancy (Fig. 1a) (raw CT values in Additional
file 3: Table S2). There was a significant (p = 0.006) in-
crease in Rxfp1 mRNA in Rln+/+ mice on days 3 and 4
of pregnancy compared with day 1 (Fig. 1b). A
Fig. 2 RXFP1 receptor localization in tissues in the uterus of non-pregnant wild type and Rxfp1-transgenic mice. Strong positive staining for
β-galactosidase activity (blue) indicates RXFP1. s = stroma; l = lumen; e = luminal epithelium; cm = circular layer of myometrium; lm = longitudinal
layer of myometrium. Magnifications are indicated on the left
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Table 1 Selected genes modulated by human recombinant relaxin treatment of human endometrial stromal cells in vitro
Category Gene Accession number Fold-change
Angiogenesis related Tissue inhibitor of metalloproteinase-3 NM_000362 +1.9
Hypoxia-inducible factor 1, alpha subunit NM_001530 +1.5
Hepatocyte growth factor NM_000601 +1.5
Angiogenin NM_001145 +1.4
Vascular endothelial growth factor A NM_001025366 +1.2
Vascular endothelial growth factor D NM_004469 - 0.3
Angiogenesis inhibitors CD36 NM_001001548 - 0.3
Hemostasis/menses correlated Matrix metalloproteinase-7 NM_002423 - 0.4
Tissue plasminogen activator NM_000930 - 0.3
Secretory phase expression Interleukin 1 receptor-like 1 NM_003856 +1.5
CD44 NM_000610 - 0.3
Proliferative phase expression Tenascin C NM_002160 - 0.4
Androgen receptor NM_000044 - 0.3
Renin-angiotensin system Renin NM_000537 +1.4
Angiotensin II receptor 1 NM_000685 +1.4
Angiotensin II receptor 2 NM_000686 - 0.3
Growth factors/cytokines Insulin-like growth factor binding protein 4 NM_001552 +1.4
Insulin-like growth factor 1 NM_001111284 +1.4
Osteoclast stimulating factor 1 NM_012383 +1.4
Amphiregulin NM_001657 +1.4
Connective tissue growth factor NM_001901 - 0.3
Structural proteins Dystrophin NM_004011 +1.6
Claudin 10 NM_006984 +1.5
Tetraspan 3 NM_005724 +1.4
Myosin X NM_012334 +1.4
Contactin 1 NM_001843 +1.4
Keratocan NM_007035 - 0.5
Matrin 3 NM_199189 - 0.3
Sorcin NM_003130 - 0.3
Cadherin-2 NM_001792 - 0.3
Tight junction protein 1 NM_003257 - 0.3
Extracellular matrix Fibronectin NM_212482 - 0.3
Nidogen (entactin) NM_002805 - 0.3
Metabolism Glycerol kinase NM_203391 +2.0
Acyl-Coenzyme A dehydrogenase NM_000016 +1.6
Ceruloplasm NM_000096 +1.4
Transferrin NM_001063 +1.4
Enzymes/inhibitors Heparin cofactor II NM_000185 +1.8
Serine protease inhibitor NM_001127698 +1.5
Carboxypeptidase B2 NM_001872 +1.5
Aminoacylase 1 NM_000666 +1.4
Cathepsin B NM_001908 - 0.3
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comparison between genotypes revealed a significant (p =
0.003) increase in Rxfp1 expression on day 1 in Rln-/- mice
compared to day 1 in Rln+/+ mice but expression on day 4
of pregnancy was similar between Rln+/+ and Rln-/- mice
(Fig. 1b). Rln mRNA was detected at all stages in the ovar-
ies of the wild type mice (Fig. 1c). Rln mRNA was also de-
tected in whole uterus, with significantly increased
expression on days 3 and 4 of pregnancy relative to day 1
(p < 0.05) (Fig. 1c and d).
Strong positive staining for Rxfp1-specific β-galactosidase
activity was identified in the myometrium of Rxfp1TG mice,
particularly in the inner circular muscle layer (Fig. 2). Upon
closer examination of the endometrium, positive staining
for Rxfp1-specific β-galactosidase activity was seen in the
stroma towards the luminal epithelium. The negative con-
trol used in this study was the uterus of a wild type mouse,
which showed no endogenous or background β-
galactosidase activity (Fig. 2). This confirmed that the
β-galactosidase activity observed in the Rxfp1TG mouse
uterus was specific and represents localization of Rxfp1.
Effects of relaxin on angiogenesis-related gene expression
in human endometrial stromal cells
A total of 321 genes were upregulated (by 1.4-fold or
more) in HES cells incubated with rhRLX for 24 h,
whereas 203 genes were down-regulated by at least
30 %. 64 well characterized genes increased with relaxin
treatment (Table 1), of which glycerol kinase showed the
largest increase (2-fold). A number of genes whose ex-
pression is associated with regulation of angiogenesis
were among those modulated by rhRLX. Timp3 (1.9-
fold), Hgf, (1.5-fold) Hif1α (1.5-fold) and angiogenin
(1.4-fold) were increased. The expression of VEGF was
analyzed as 1.2-fold higher in relaxin-treated cells,
within the noise of the assay. In contrast, VEGF-D and
CD36 were decreased by 30 %. CD36 thought to be an
inhibitor of angiogenesis [33] was down-regulated by
30 % after rhRLX treatment.
Gene expression in the uterus of early pregnant Rln+/+
and Rln-/- mice
Consistent with prior studies [34], there was a modest
increase in VegfA on day 4 of pregnancy compared with
day 1 in the wild type mice in study 2 (p = 0.012)
(Fig. 3a). A comparison between genotypes demon-
strated a significant (p = 0.026) increase in VegfA on day
1 of pregnancy in the Rln-/- mice compared with the
same time point in Rln+/+ mice. Similarly, there was a
significant (Day 3: p = 0.006; Day 4: p = 0.002) increase
in Vegfr2 on days 3 and 4 of pregnancy in Rln+/+ mice
Table 1 Selected genes modulated by human recombinant relaxin treatment of human endometrial stromal cells in vitro
(Continued)
Transcription factors Kruppel-like factor-1 NM_006563 +1.5
Eukaryotic translation termination factor 1 NM_004730 +1.5
Eukaryotic translation initiation factor 3 NM_003758 +1.5
Transactivator jun-B NM_002229 +1.4
Protein kinases Mitogen-activated protein kinase 4 NM_002747 +1.5
Protein kinase, cAMP-dependent regulatory NM_002734 +1.4
Calcium/calmodium protein kinase I NM_003656 +1.4
Calcium/calmodium protein kinase II NM_172127 +1.4
Protein kinase, cAMP-dependent catalytic NM_002731 - 0.4
Mitogen-activated protein kinase 1 NM_002745 - 0.3
Cyclin G1 NM_004060 - 0.3
Receptors Retinal G-protein coupled receptor NM_002921 +1.5
Hyaluronan-mediated motility receptor NM_001142556 +1.4
Vasoactive intestinal peptide receptor 2 NM_003382 +1.4
Activin A receptor IB NM_004302 - 0.3
Chemokine receptor 1 NM_001295 - 0.3
Others Lacrimal proline-rich protein NM_007244 +1.6
Trefoil factor-1 NM_003225 +1.6
Amyloid precursor protein binding protein-2 NM_006380 +1.5
Neurogenic differentiation 1 NM_002500 +1.5
Annexin A3 NM_005139 +1.5
Basonuclin 1 NM_001717 - 0.5
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compared with day 1 but there was no effect of genotype
(Fig. 3b).
Because relaxin is known to modulate steroid receptor
expression [9], Esr1 and Esr2 transcripts were examined
(Pgr was also examined, see below). Esr1 but not Esr2
was significantly (Day 2: p = 0.01; Day 3: p = 0.002; Day
4: p = 0.004) increased in Rln+/+ mice on days 2, 3 and 4
of pregnancy. Only Esr1 expression was significantly
(pregnancy: p ≤ 0.001; genotype: p = 0.002) affected by
both pregnancy and genotype (Fig. 3c and d).
Mmp14 and Timp3 were also significantly (Mmp14:
Day 3: p = 0.012; Day 4: p = 0.003, Timp3: Day 3: p =
0.019; Day 4: p = 0.004) upregulated on days 3 and 4
compared with day 1 in pregnant Rln+/+ mice (Fig. 4).
Interestingly, Mmp14 was significantly (p = 0.001) higher
in Rln-/- mice on day 1 of pregnancy compared with the
Rln+/+ counterpart, whereas there was no significant ef-
fect of genotype on Timp3 expression. However Timp3
was significantly (pregnancy: p ≤ 0.001) higher on day 4
of pregnancy compared with day 1 in both genotypes in
study 2.
Based on the data from the microarray study of HES
cells (Table 1), we analyzed four other genes that were al-
tered by relaxin treatment. In wild type mice, there was
no significant increase in Ankrd37 from days 1 to day 4 of
pregnancy (Fig. 5a). A comparison of genotypes demon-
strated a significant (p = 0.011) increase in Ankrd37 on
day 1 in the Rln-/- mice compared with Rln+/+. Egln1 was
significantly (p = 0.015) upregulated on day 4 of pregnancy
in Rln+/+ mice compared to days 1 and 2 (Fig. 5b). There
was also a significant (p ≤ 0.001) difference between the
genotypes on day 1. Both Hgf and Hif1α were significantly
(p < 0.05) increased on days 3 and 4 in the wild type mice
compared to day 1 of pregnancy (Fig. 5c and d). Hif1α ex-
pression was significantly (p = 0.008) upregulated in the
Rln-/- mice on day 1 compared with Rln+/+ but there was
no difference in Hgf between the genotypes.
We also examined expression of the genes noted above
in uteri from day 6 pregnant mice, but no significant dif-
ferences were observed between Rln+/+ and Rln-/- mice
(Additional file 1: Figure S1).
Pre-implantation endometrial angiogenesis
Endothelial cell proliferation occurred in the endomet-
rium on day 4 but not day 1 of pregnancy in wild type
Fig. 3 Expression of (a) VegfA total, (b) Vegfr2, (c) Esr1 and (d) Esr2 in
the uterus of Rln+/+ mice on days 1 to 4 of pregnancy (Study 1), and
in Rln+/+ and Rln-/- mice on days 1 and 4 of pregnancy (Study 2) (n =
6–8). Horizontal bars indicate mean values. Groups within each study
that do not share a letter are significantly different from one another,
*denotes a significant difference between day 1 and 4 of pregnancy in
study 2, significance is p < 0.05
Fig. 4 Expression of extracellular matrix remodeling genes (a) Mmp14
and (b) Timp3 in the uterus of Rln+/+ mice from days 1 to 4 of
pregnancy (Study 1) and in Rln+/+ and Rln-/- mice on days 1 and 4 of
pregnancy (Study 2) (n = 6–8). Horizontal bars indicate mean values.
Groups within each study that do not share a letter are significantly
different from one another, *denotes a significant difference between
day 1 and 4 of pregnancy in study 2, significance is p < 0.05
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mice, consistent with a previous report [6]. Proliferation
in the Rln-/- mice also occurred on day 4 (Fig. 6). How-
ever, there was no significant difference in the percent-
age of vessel profiles containing proliferating endothelial
cells or the number of proliferating endothelial cells in
the endometrium per mm2 between the genotypes. Add-
itionally, there was no difference in the number of ves-
sels per mm2 (data not shown).
Plasma progesterone and corticosterone concentrations
As seen in previous studies [6], there was a significant
(p ≤ 0.001) effect of day of pregnancy on circulating pro-
gesterone levels in the wild type and relaxin deficient
mice from day 1 to day 4 of pregnancy (Fig. 7a). Plasma
progesterone concentrations were significantly (p =
0.013) different between the two genotypes on day 4,
with an increase in progesterone in the Rln-/- mice rela-
tive to the Rln+/+ mice. There was a significant (Day 1:
p = 0.017; Day 4: p = 0.005) increase in Pgr in Rln-/- mice
compared to Rln+/+ mice on days 1 and 4 of pregnancy
(Fig. 7b). Circulating corticosterone levels were signifi-
cantly (p = 0.003) higher on day 1 compared with day 4
of pregnancy in both Rln+/+ and Rln-/- mice (Fig. 7c) but
there was no difference between the genotypes.
Discussion
The aims of this study were to confirm expression of re-
laxin and its receptor RXFP1 in the whole uterus of early
pregnant mice prior to implantation and examine the ef-
fects of relaxin deficiency on endometrial angiogenesis
and the expression of key angiogenesis-related and extra-
cellular matrix remodeling genes in the pre-implantation
period. Because fetal growth is compromised in Rln-/-
mice, and relaxin is thought to play a role in vascular
growth in the endometrium in primates, our prediction
was that pre-implantation angiogenesis in the endomet-
rium would be compromised in Rln-/- mice. In fact, we ob-
served that blood vessel proliferation was not different in
Rln-/- mice compared to wild types before implantation.
Unexpectedly, this was despite a general increase in the
expression of many angiogenesis-related and other re-
modeling genes in the uteri of Rln-/- mice compared to
wild type animals, particularly on day 1 of pregnancy. Re-
laxin deficiency was also associated with an increase in cir-
culating progesterone levels and progesterone receptor
mRNA expression. Overall, our data demonstrate
phenotypic changes in the pre-implantation uterus of
Rln-/- mice that include enhanced expression of steroid
receptors, angiogenesis and matrix remodeling-related
genes, but without the predicted impact on endometrial
angiogenesis.
Circulating relaxin is undetectable in mice in early
pregnancy [35] but relaxin gene transcripts were de-
tected in the ovaries and uterus from day 1 of preg-
nancy. The surprising finding was the high expression of
relaxin on day 3 of pregnancy for which we have no ex-
planation. Previous studies have shown relaxin gene ex-
pression in the uterus of early pregnant pigs [36] and in
HES cells in culture [21]. These data provide good evi-
dence that relaxin is locally produced and can act in a
paracrine fashion in the uterus. It was also important to
demonstrate Rxfp1 expression in the uterus of mice in
early pregnancy. Rxfp1 increased between days 1 and 4
of pregnancy in both Rln+/+ and Rln-/- mice. In fact,
Rxfp1 was higher in Rln-/- mice at the start of pregnancy.
Increased Rxfp1 expression has also been shown in the
cervix and vagina of Rln-/- mice [37] but not in the myo-
metrium in late pregnancy [38]. This suggests differential
Fig. 5 Expression of (a) Ankrd31, (b) Egln1, (c) Hgf and (d) Hif1α in
the uterus of Rln+/+ mice from days 1 to 4 of pregnancy (Study 1)
and in Rln+/+ and Rln-/- mice on days 1 and 4 of pregnancy (Study 2)
(n = 6–8). Horizontal bars indicate mean values. Groups within each
study that do not share a letter are significantly different from one
another, *denotes a significant difference between day 1 and 4 of
pregnancy in study 2, significance is p < 0.05
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regulatory effects of the relaxin ligand on its own recep-
tors dependent on tissue and stage of pregnancy [39].
LacZ staining demonstrated that RXFP1 was localized
predominantly in the inner circular layer of the myome-
trium, but also in the endometrial stroma similar to that
shown by Kamat et al [26]. However, this observation
was made in non-pregnant mice, so it is possible that
the pattern of RXFP1 staining may differ in early preg-
nant mice, likely intensified in the endometrium. Several
studies have reported high expression of immunoreac-
tive RXFP1 in endometrial stromal cells in uterine sam-
ples from women during the menstrual cycle [17, 18]
but this was not substantiated in later studies in which
RXFP1 mRNA and relaxin binding sites were predomin-
antly found in glandular and luminal epithelial cells [19].
No studies to date have assessed RXFP1 in early preg-
nancy in relation to angiogenesis. In women, there was
an increase in RXFP1 in endometrial biopsies collected
during the secretory phase relative to those from the
proliferative phase [19]. It was not established if changes
in RXFP1 occurred in stromal, epithelial or endothelial
cells within the endometrium. However, Kohsaka et al
[40] identified relaxin binding sites in epithelial cells,
smooth muscle cells, and blood vessels in the cervix, va-
gina and uterus in tissues obtained from women after
hysterectomy. RXFP1 has been localized specifically to
endothelial cells [41, 42] in systemic and uterine blood
vessels, but it remains to be demonstrated if relaxin re-
ceptors are expressed in endometrial endothelial cells in
early pregnancy.
Because HES cells have previously been shown to ex-
press high affinity relaxin binding sites [15] and to se-
crete cAMP [27] and VEGF [15] in response to relaxin,
these cells were used to screen for other potentially rele-
vant genes upregulated by relaxin. Our microarray ana-
lysis of gene transcripts altered by relaxin in HES cells
revealed a number of genes whose expression is associ-
ated with stimulation of angiogenesis, including Timp3,
Hgf, and Hifiα. These and other genes known to modu-
late steroid responsiveness, angiogenesis and extracellu-
lar remodeling, including Esr1, VegfA, Vegfr2, Pgr, Elgn1,
Mmp14 and Ankrd37, were investigated in the mouse
uterus by quantitative analysis. Genes including Esr1,
Hgf, Hif1α, Timp3, VegfA, Vegfr2 and Pgr were all upreg-
ulated by day 4 of pregnancy in the uterus of Rln+/+
mice relative to day 1. This correlates well with previ-
ously published data [34, 43–46]. In addition, two other
novel genes were upregulated in the uterus of early preg-
nancy, Egln1 and Mmp14. The latter remodels the ECM
by activating other MMPs including MMP2 [47].
Fewer genes were analyzed in the in vivo study in
mice; surprisingly, there was a significant increase in
most of the genes examined on day 1 of pregnancy in
the Rln-/- mice. Most notably, there was a large increase
in Pgr and Esr1, but not Esr2, as well as an increase in
circulating progesterone on day 4. This contrasts with
previous work that demonstrated increases in Esr2, but
not Esr1, in the cervix and vagina of late pregnant Rln-/-
mice [37]. These differences may simply be due to
tissue-specific expression or because we investigated the
Fig. 6 Representative photomicrograph of CD31 (blue, pan-endothelial cell marker) and BrdU (brown, proliferating cell marker) immunostaining in
the endometrium of a (a) wild type (Rln+/+) and (b) relaxin deficient (Rln-/-) mice on day 4 of pregnancy. Black arrow indicates blood vessel profile;
* = proliferating endothelial cells; g = gland; s = stroma; m =myometrium. c Percentage of vessel profiles containing proliferating endothelial cells
(%) and the (d) number of proliferating endothelial cells per mm2 in the endometrium of Rln+/+ and Rln-/- mice on days 1 and 4 of pregnancy
(n = 5–7). Horizontal lines indicate mean values. Each triangle represents data from an individual mouse
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uterus prior to implantation, a time when the steroid
hormone profile is very different to that later in preg-
nancy. Treatment of ovariectomized rhesus monkeys
with relaxin reduces endometrial progesterone receptor
isoforms A and B, and ERα, without effecting ERβ [9].
These data support our findings in the Rln-/- mice, and
indicate a role for endogenous relaxin in the regulation
of these receptors. Additionally, this accelerated increase
in Pgr in the Rln-/- mice could indirectly mediate the in-
creased expression of the angiogenesis and extracellular
matrix remodeling related genes on day 1 of pregnancy;
further, we suggest that increased plasma progesterone
levels, with increased expression of progesterone recep-
tors, may be sufficient to compensate for the lack of re-
laxin in the stimulation of angiogenesis.
Another surprising finding was the increased VegfA
expression in Rln-/- mice on day 1 of pregnancy. Relaxin
stimulates expression and secretion of VEGF in human
endometrial stromal and glandular epithelial cells in a
dose-dependent manner in vitro [15, 21]. Therefore, we
had predicted that in the absence of relaxin in early
pregnancy,VegfA would be compromised. However, pro-
gesterone mediates its angiogenic effects partly through
VEGF so the enhanced progesterone/Pgr expression on
day 1 of pregnancy in Rln-/- mice could explain the in-
crease in VegfA expression.
Similarly, given the rhRLX-induced increase in Hgf
and Hif1α in the human microarray study, we antici-
pated that expression of these genes would be decreased
in the uterus of the Rln-/- mice. This was not the case.
The significance of the increased expression of VegfA,
Esr1, Egln1, Hif1α, Mmp14 and Ankrd37 in the Rln-/-
mice on day 1 of pregnancy is unknown. One possibility
is that in the absence of relaxin, the estrous cycle is
modified, with a shorter follicular phase and more rapid
onset of estrus. Although our mice were synchronized
around estrus, they could mate any time between 4 pm
and 8 am when they were first checked for mating plugs.
If the Rln-/- mice had shorter estrous cycles, they could
mate up to 12 h before Rln+/+ mice, and therefore post-
coital stimuli that trigger changes in the uterine environ-
ment would be accelerated in Rln-/- mice. Of interest,
circulating corticosterone levels were significantly ele-
vated in both genotypes on day 1 of pregnancy relative
to day 4, suggesting a possible stress response to mating
and/or human contact post-coitus.
There are two noteworthy limitations in our study.
First, our gene analysis used the whole uterus because
it was not possible to separate the endometrium from
the myometrium in the mouse uterus in early preg-
nancy and yield sufficient quantities of high quality
RNA. We acknowledge that the homogenized uteri
contain both endometrium and myometrium, and that
there are spatiotemporal differences in the genes ana-
lyzed. Thus it is possible that relaxin deficiency could
affect spatiotemporal gene expression. This could only
be assessed through in situ hybridization. Second, we
used HES cells in the microarray analysis to identify
genes targeted by relaxin. Patterns of relaxin secretion
vary in humans and rodents, with relaxin peaking in
the first trimester in humans [48] and increasing
throughout pregnancy in rodents [35, 49]. Furthermore,
endometrial angiogenesis occurs in women before the
arrival of the blastocyst and primarily occurs in mice
after implantation. Therefore the role of relaxin in
these two species could be quite different, and the pre-
implantation uterus may not be a substantial relaxin
target in mice. Importantly, we would argue that
relaxin-deficient mice are not an appropriate animal
Fig. 7 a Plasma progesterone concentrations, (b) expression of
progesterone receptor (Pgr) and (c) plasma corticosterone concentration
in wild type (Rln+/+) and relaxin deficient (Rln-/-) mice on days 1 and 4 of
pregnancy (n= 4–9). Horizontal lines indicate the mean. Groups within
each study that do not share a letter are significantly different from one
another, *denotes a significant difference between day 1 and 4 of
pregnancy in study 2, significance is p< 0.05
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model to further investigate the role of relaxin in the
pre-implantation uterus in humans.
Conclusion
In conclusion, we have demonstrated that relaxin defi-
ciency in mice results in phenotypic changes in the
pre-implantation uterus including differential expres-
sion of steroid receptor and angiogenesis/remodeling
related genes and increased circulating progesterone.
Consistent with previously published data, there was
an increase in endometrial endothelial cell prolifera-
tion by day 4 of pregnancy in the Rln+/+ mice [6]; this
was also seen in the Rln-/- mice. However, there was no
significant decrease in endometrial angiogenesis in the
relaxin deficient mice. Nor was there accelerated blood
vessel proliferation on day 1 of pregnancy in Rln-/-
mice despite the increased expression of angiogenesis-
related genes. Therefore, we conclude that endogenous
relaxin does not play a major role in pre-implantation
angiogenesis in the mouse uterus.
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